Journal
PHARMACEUTICAL RESEARCH
Volume 29, Issue 10, Pages 2902-2911Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-012-0797-2
Keywords
combretastatin A-4; doxorubicin; octreotide; programmed release; spatiotemporally controlled co-delivery; targeted delivery
Funding
- National Nature Science Foundation [81130059]
- National Basic Research Program of China [2009CB930300]
Ask authors/readers for more resources
Both combretastatin A-4 (CA-4) and doxorubicin (DOX) was loaded in different form in a targeted nanomedicine in order to achieve the active delivery of these two drugs followed by sequentially suppressing tumor vasculature and tumor cells. Octreotide-modified stealth liposomes loaded with CA-4 and DOX (Oct-L[CD]) were prepared and characterized. Then in vitro release, cellular uptake, in vitro antitumor effect, pharmacokinetics, in vivo sequential killing effect, in vivo antitumor efficacy against somatostatin receptor (SSTR) positive cells, as well as the action mechanism of such system, were studied. A rapid release of CA-4 followed by a slow release of DOX was observed in vitro. The active targeted liposomes Oct-L[CD] showed a specific cellular uptake through ligand-receptor interaction and a higher antitumor effect in vitro against SSTR-positive cell line. The in vivo sequential killing effect of such system was found as evidenced by the fast inhibition of blood vessels and slow apoptosis-inducing of tumor cells. Oct-L[CD] also exhibited the strongest antitumor effect in MCF-7 subcutaneous xenograft models. Oct-modified co-delivery system may have great potential as an effective carrier for cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available